Cellectis S.A. CLLS

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $72.9M$41.5M$755.0K$19.2M$30.3M$51.1M$15.2M$12.7M$25.2M$44.8M
Operating income -$33.1M-$59.6M-$97.3M-$89.7M-$103.5M-$42.3M-$123.6M-$105.1M-$92.7M-$67.3M
Net income -$67.6M-$36.8M-$108.4M-$114.0M-$125.1M-$97.5M-$115.2M-$88.3M-$103.7M-$67.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets $324.7M$383.5M$334.3M$261.2M$382.1M$469.5M$467.5M$500.8M$332.9M$331.4M
Total equity $75.9M$131.0M$84.7M$125.9M$236.5M$308.8M$355.5M$450.3M$284.0M$273.0M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-116428.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -150M -100M -50M 0 50M 100M Revenue, FY2016: 44.8M Net income, FY2016: -67.3M Revenue, FY2017: 25.2M Net income, FY2017: -103.7M Revenue, FY2018: 12.7M Net income, FY2018: -88.3M Revenue, FY2019: 15.2M Net income, FY2019: -115.2M Revenue, FY2020: 51.1M Net income, FY2020: -97.5M Revenue, FY2021: 30.3M Net income, FY2021: -125.1M Revenue, FY2022: 19.2M Net income, FY2022: -114M Revenue, FY2023: 755K Net income, FY2023: -108.4M Revenue, FY2024: 41.5M Net income, FY2024: -36.8M Revenue, FY2025: 72.9M Net income, FY2025: -67.6M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $44.8M $25.2M $12.7M $15.2M $51.1M $30.3M $19.2M $755.0K $41.5M $72.9M
Gross profit — — — — — — — — — —
Net income -$67.3M -$103.7M -$88.3M -$115.2M -$97.5M -$125.1M -$114.0M -$108.4M -$36.8M -$67.6M

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%